Compare Charles River Laboratories Intl. Inc (CRL) vs Elastic NV (ESTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Elastic NV — how do they compare? Charles River Laboratories Intl. Inc trades at $300.35 (market cap $14.23B), while Elastic NV trades at $96.33 (market cap $10.00B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Elastic NV is more actively traded (1,610,337 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Elastic NV for 10 Days on average.
| CRL | ESTC | |
|---|---|---|
Market Cap | $14.23B | $10.00B |
Volume | 1,176,885 | 1,610,337 |
Sector | Health | Technology |
52-Week High | $310.77 | $99.91 |
52-Week Low | $149.93 | $43.30 |
Typical Hold Time | 33 Days | 10 Days |
Enterprise Value | $17.06B | $9.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Elastic (ESTC) trades at $96.44, up 3.59% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches in AI and observability platforms highlight innovation, while profitability metrics show improvement into 2026. The current price sits near resistance at $97, with RSI indicating potential overbought conditions short-term.
Outlook remains positive given earnings momentum and product expansion, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though bullish sentiment prevails with 65% buy ratings. Investors should weigh growth potential against execution risks in a competitive software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
